Vikram Narayan, MD, discussed the durable clinical activity observed with nadofaragene firadenovec in the CS-003 trial for patients with non-muscle invasive bladder cancer. A long-term analysis of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback